Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer
The hypothesis of this study is to discover if the oral Etoposide plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC.

It is a single-arm, multicenter phase II clinical study of oral etoposide combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer
Triple Negative Breast Cancer
DRUG: oral etoposide + anlotinib
objective response rate（ORR）, The ORR will be defined as the proportion of patients in the Efficacy Evaluable patient Set who achieve complete response (CR) and partial response (PR), up to 1 year after the last patient enrolled
Progression free survival（PFS）, PFS will be defined as the time from first dose of study drug until documentation of disease progression or death from any cause, up to 1 year after the last patient enrolled|Incidence and Severity of adverse events, hematologic，hepatotoxicity，Incidence of hypertension，Incidence of proteinuria, approximately 1.5 years
It is a single-arm, multicenter phase II clinical study of oral etoposide combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer.

The hypothesis of this study is to discover if the oral Etoposide plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC.